V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10423209 | 10065006 | null | 73.95 | Palliative (P) | 2020-11-29 | 2020-12-20 | R-GDP | 02 | null | BLEOMYCIN | 100991386 |
| 10423408 | 10065009 | 1.66 | 85.75 | Curative (C) | 2019-03-30 | 2019-05-10 | Doxorubicin + Olaratumab | 02 | N | TRANSPLANT ALEMTUZUMAB + FLUDARABINE + MELPHALAN | 101443785 |
| 10423604 | 10065011 | 1.64 | 82.6 | null | 2022-01-22 | 2022-02-23 | EVEROLIMUS | 02 | null | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100206028 |
| 10424217 | 10065015 | 1.8 | 71 | null | 2021-10-31 | 2021-12-03 | Cytarabine High Dose | null | null | ATEZOLIZUMAB + BEVACIZUMAB | 100797611 |
| 10424249 | 10065016 | 1.82 | 73.4 | null | 2017-01-28 | 2018-02-25 | Trial Unspecified | 99 | null | INTERFERON ALFA | 101457484 |
| 10424593 | 10065019 | 1.81 | 82.8 | Palliative (P) | 2016-10-20 | 2016-10-27 | Bevacizumab+Carbo+Pacliaxel | 02 | N | CETUXIMAB + FLUOROURACIL + OXALIPLATIN | 101145112 |
| 10424962 | 10065021 | 0 | 0 | 03 | 2017-11-25 | 2017-11-25 | TRASTUZUMAB EMTANSINE | 02 | N | VINBLASTINE | 100264363 |
| 10425011 | 10065023 | null | null | Disease modification (D) | 2019-04-12 | 2019-04-22 | EVEROLIMUS + EXEMESTANE | 02 | null | CAR-T AXICABTAGENE CILOLEUCEL + CYCLOPHOSPHAMIDE + FLUDARABINE | 100617632 |
| 10425272 | 10065026 | null | null | Disease modification (D) | 2017-07-20 | 2017-08-22 | Etoposide oral | 02 | N | BCG | 100998880 |
| 10425497 | 10065027 | null | null | null | 2019-08-16 | 2019-09-06 | FLAIR trial | 02 | null | CYCLOPHOSPHAMIDE + LENALIDOMIDE | 100315768 |
| 10425742 | 10065028 | 1.85 | 90 | 03 | null | 2019-04-27 | Eribulin | 02 | N | CARBOPLATIN + PEMBROLIZUMAB + PEMETREXED | 101324934 |
| 10425971 | 10065032 | 1.67 | 61.6 | Neo-adjuvant (N) | 2021-06-01 | 2021-06-01 | Exemestane + Palbociclib | 02 | N | FULVESTRANT + PALBOCICLIB | 100173553 |
| 10426008 | 10065033 | 1.89 | 67.7 | null | 2018-09-28 | 2018-09-28 | Pemetrexed | 02 | null | TRASTUZUMAB EMTANSINE | 100681031 |
| 10426107 | 10065036 | 1.73 | 103.6 | null | 2019-10-22 | 2019-10-22 | Ixazomib | 02 | null | GO2 TRIAL | 100900217 |
| 10426523 | 10065038 | 1.64 | 83.8 | Adjuvant (A) | 2018-08-17 | 2018-08-17 | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | 02 | null | CYTARABINE | 100706425 |
| 10426776 | 10065039 | 1.77 | 86.5 | null | 2017-10-10 | 2017-10-14 | Cytarabine + Venetoclax | 01 | null | BORTEZOMIB + CISPLATIN + CYCLOPHOSPHAMIDE + DOXORUBICIN + ETOPOSIDE + THALIDOMIDE | 101449159 |
| 10426962 | 10065040 | 1.55 | 60.2 | null | null | 2019-08-13 | FEC 60 or 75 | 01 | null | BEXAROTENE | 100865963 |
| 10426982 | 10065041 | 1.64 | 46.5 | null | 2016-04-09 | 2019-04-21 | FEC 60 or 75 | 02 | null | DURVALUMAB | 100019271 |
| 10427069 | 10065042 | 0 | 80 | 03 | 2010-08-11 | 2018-05-20 | Pemetrexed | null | N | IDELALISIB + RITUXIMAB | 100499022 |
| 10427505 | 10065043 | null | null | Palliative (P) | 2021-02-02 | 2021-02-02 | Sorafenib | 02 | N | CYCLOPHOSPHAMIDE + DOCETAXEL + TRASTUZUMAB | 100477650 |
| 10427754 | 10065044 | 1.69 | 65.2 | null | 2021-03-21 | 2021-04-05 | Pazopanib | 02 | null | FCR | 101263695 |
| 10427838 | 10065045 | 1.72 | 72.5 | null | 2018-08-01 | 2018-08-22 | ISATUXIMAB | 02 | null | ABVD | 100875392 |
| 10428479 | 10065047 | 1.59 | 77 | Palliative (P) | 2017-01-14 | 2017-04-29 | IDELALISIB + RITUXIMAB | 02 | N | CARBOPLATIN + PEMBROLIZUMAB + PEMETREXED | 101214293 |
| 10428829 | 10065051 | 1.69 | 69.5 | 03 | 2020-08-03 | 2020-08-10 | R-CHOP / R-DHAP | 02 | N | DASATINIB | 101416010 |
| 10428839 | 10065052 | 1.69 | 83.5 | null | 2014-05-04 | 2019-03-25 | Cyclophos + Dex + Lenalidomide | null | null | DURVALUMAB | 101700664 |
| 10429134 | 10065053 | 1.66 | 60.4 | Palliative (P) | null | 2019-02-17 | R GCVP | 02 | N | ANAGRELIDE | 100242224 |
| 10429154 | 10065054 | null | null | Palliative (P) | 2021-02-06 | 2021-02-21 | DOCETAXEL + FLUOROURACIL + OXALIPLATIN | 02 | N | CYCLOPHOSPHAMIDE + RITUXIMAB | 100197176 |
| 10429245 | 10065056 | 1.55 | 57 | null | 2020-06-14 | 2020-06-22 | CYCLOPHOSPHAMIDE + DOCETAXEL + EPIRUBICIN | 02 | null | CYCLOPHOSPHAMIDE + ETOPOSIDE + RITUXIMAB + VINCRISTINE | 101686829 |
| 10429259 | 10065057 | 1.64 | 66.7 | null | 2017-06-11 | 2019-08-08 | LEAM | 02 | null | CISPLATIN + RT | 101488142 |
| 10429313 | 10065058 | 1.61 | 103 | Palliative (P) | 2021-04-22 | 2021-05-01 | R Chlorambucil | 02 | N | ABEMACICLIB + FULVESTRANT | 100516871 |
| 10429360 | 10065059 | 1.58 | 58.75 | Palliative (P) | 2020-03-06 | 2020-03-18 | LIPOSOMAL DAUNORUBICIN + CYTARABINE (Vyxeos) | 02 | N | BEXAROTENE | 101389522 |
| 10429476 | 10065060 | 1.56 | 77.3 | Adjuvant (A) | 2014-01-08 | 2018-07-02 | R IVAC | 02 | N | CARBOPLATIN + CYCLOPHOSPHAMIDE + EPIRUBICIN + PACLITAXEL | 100699439 |
| 10429607 | 10065061 | 0 | 80.1 | Neo-adjuvant (N) | 2018-10-23 | 2019-01-16 | Cytarabine Low Dose | 02 | N | CISPLATIN + GEMCITABINE + RITUXIMAB | 100469914 |
| 10429639 | 10065062 | 1.67 | 82.1 | Curative (C) | 2019-11-09 | 2019-11-11 | Neratinib | 02 | N | CYCLOPHOSPHAMIDE + DOCETAXEL | 100996160 |
| 10430229 | 10065067 | 1.53 | null | null | null | 2019-03-01 | LANREOTIDE | 02 | null | ABEMACICLIB + FULVESTRANT | 100505190 |
| 10430234 | 10065068 | 1.66 | 58 | Palliative (P) | 2018-11-14 | 2018-11-24 | Pazopanib | 02 | N | CYTARABINE | 100028405 |
| 10430429 | 10065070 | null | null | 03 | 2021-11-04 | 2021-11-28 | CARFILZOMIB | 02 | N | DOXORUBICIN | 100305062 |
| 10430513 | 10065071 | 1.74 | 69.8 | 03 | null | 2019-02-25 | ISATUXIMAB + POMALIDOMIDE | 02 | N | STAMPEDE TRIAL | 101149832 |
| 10430640 | 10065072 | 1.52 | 101.8 | null | 2020-03-14 | 2020-11-07 | Olaparib | 02 | null | BORTEZOMIB + DARATUMUMAB + THALIDOMIDE | 100014383 |
| 10430766 | 10065074 | 1.71 | 96 | Neo-adjuvant (N) | 2017-06-28 | 2017-07-01 | Obinutuzumab +CVP | 02 | N | STAMPEDE TRIAL | 101304162 |
| 10430927 | 10065075 | null | null | null | 2021-07-15 | 2021-08-15 | CAPECITABINE + EPIRUBICIN + OXALIPLATIN | 02 | null | BOSUTINIB | 101607791 |
| 10431072 | 10065076 | 1.74 | 70 | Palliative (P) | 2021-02-14 | 2021-03-02 | Rucaparib | 02 | N | CISPLATIN + GEMCITABINE + RITUXIMAB | 100546999 |
| 10431192 | 10065077 | 1.53 | 79.7 | null | 2021-02-26 | 2021-09-26 | Mitomycin Intravesical | 02 | N | LOMUSTINE | 101121873 |
| 10431396 | 10065080 | null | null | Palliative (P) | 2019-01-08 | 2019-10-01 | null | Y | N | DURVALUMAB | 101036371 |
| 10431408 | 10065081 | 1.64 | 69.35 | 03 | 2021-08-21 | 2021-08-24 | DTPACE | 02 | N | IXAZOMIB | 100352002 |
| 10431550 | 10065082 | 1.6 | 50.2 | Palliative (P) | null | 2019-08-26 | OSIMERTINIB | N | N | TOPOTECAN | 101823083 |
| 10431586 | 10065083 | null | null | Palliative (P) | 2019-10-31 | 2019-11-22 | Irinotecan 14day | 01 | N | CHLORAMBUCIL + RITUXIMAB | 100908116 |
| 10431812 | 10065084 | 1.5 | 58.5 | null | 2018-08-24 | 2018-09-09 | null | N | null | DOCETAXEL + NINTEDANIB | 100921645 |
| 10432618 | 10065086 | 1.69 | 56.7 | Palliative (P) | 2020-04-29 | 2020-05-03 | Cisplatin + Pemetrexed | N | N | PARTNER TRIAL | 101261049 |
| 10432730 | 10065089 | null | null | Adjuvant (A) | null | 2019-08-28 | EVEROLIMUS + EXEMESTANE | 02 | N | CYTARABINE | 100429081 |